This strategy will allow for the identification of TCR sequences within the DP CD4+ Th TILs that recognize mutated or shared tumor antigens bound to MHC class II molecules that could then be used in TCR engineering for personalized therapies in patients with cancer. Here, CD4 is linked to neoplasm.